research An open label, multi-center clinical trial of topical 5% minoxidil solution for the treatment of male androgenetic alopecia (a phase IV study)
Topical 5% minoxidil is safe and effective for treating hair loss in Korean men.
Search
for
Sort by
Research
30-60 / 1000+ results
research 609 Topical Sandalore®, a specific OR2AT4-stimulating odorant, ameliorates female telogen effluvium: Randomized, double-blinded, placebo-controlled clinical trial
Sandalore®, a synthetic scent, improved hair loss and satisfaction in women with telogen effluvium.
research Male hormonal contraception: looking back and moving forward
New male hormonal contraceptives show promise but need more research on long-term effects and funding for larger trials.
research The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial
DHL-HisZnNa may help reduce hair loss from chemotherapy, but more research is needed.
research Advances in nucleoside monophosphate prodrugs as anti-HCV agents
New treatments for Hepatitis C show promise but need more research to confirm their safety and effectiveness for clinical use.
research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
research Comparison of a New 5% Minoxidil Foam and Rogaine® in the Treatment of Androgenetic Alopecia in Chinese Men: A Randomized, Double-Blind, Phase III, Equivalence Trial
The new 5% minoxidil foam is as effective and safe as Rogaine® for treating hair loss in Chinese men.
research A Novel Hair Restoration Technology Counteracts Androgenic Hair Loss and Promotes Hair Growth in A Blinded Clinical Trial
A new hair restoration technology was found to effectively increase hair thickness, density, and growth, while reducing hair loss and improving scalp health, with no side effects.
research 5% Minoxidil topical foam for men: Hair growth in millennials – a post hoc analysis
Using 5% minoxidil foam twice daily can help regrow hair, especially in younger men aged 20-30.
research 5% Minoxidil topical foam on women: Menopause and other covariates
5% minoxidil foam effectively regrows hair in women, with postmenopausal women seeing the most improvement.
research Alopecia in patients treated with molecularly targeted anticancer therapies
Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
research New agents for cancer chemoprevention
Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.
research c-Kit - The Novel Receptor: Physiological Roles, Downstream Signaling and Implications in Cancer
c-Kit is important for heart regeneration and cancer development.
research Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
PLD is an effective and safer alternative for treating breast cancer.
research Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
research Teriflunomide in multiple sclerosis: an update
Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
research Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist
Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
research Incidence of alopecia from endocrine therapies in cancer
Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
research PC-SPES Studies Promising, But Manufacturer Shuts Down
Promising cancer treatments were found, but the manufacturer closed.
research Efficacy and safety of a dietary supplement containing a lipid co-extract from Serenoa repens and Pygeum africanum for the treatment of androgenetic alopecia (AGA) in women. Results of a randomized, double-blind, placebo-controlled clinical trial
The supplement with Serenoa repens and Pygeum africanum significantly increased active hair growth and decreased rest phase hair in post-menopausal women with hair loss, with only mild digestive side effects.
research Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents
Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
research Getting to grips with hair loss
Finasteride improves hair growth and satisfaction in men with male pattern baldness but may cause sexual side effects.
research Bendamustine in Indolent Non-Hodgkin's Lymphoma: A Practice Guide for Patient Management
Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.
research Men??s Health
The document concludes that various drugs for men's health issues are in development, with treatments for sexual dysfunction and prostate conditions being the most advanced.
research Macrophages in Skin Wounds: Functions and Therapeutic Potential
Targeting macrophages may improve wound healing.
research Combination Therapies and the Theoretical Limits of Evidence-Based Medicine
The current system can't fully test all combination treatments, so alternative methods and regulatory flexibility are needed.
research Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
research Alopecia - the search for novel agents continues
Many potential alopecia treatments need more testing to confirm they promote acceptable hair growth with minimal side effects.
research A Comprehensive Review of Acne Treatments: Unpacking the Chemical Structures and Effective Bioactive Compounds
Understanding acne medication chemistry helps doctors treat acne better.
research Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.